Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer
"With his three decades of experience in healthcare and technology companies, Gilad will play a pivotal role in the execution of our growth strategy, and I am delighted to welcome him to the Protalix team," said Dror Bashan, Protalix's President and Chief Executive Officer. "I also want to thank Mr. Rubin, both personally and on behalf of Protalix and its Board of Directors, for his unwavering dedication and leadership. Over the last six years, Eyal and I have worked in a close, collaborative manner in the management of the Company. He contributed significantly to Protalix's transformation, strengthening the Company's capital and financial status and preparing the Company for growth. We wish Eyal success in his future endeavors."
Mr. Mamlok is a seasoned financial executive with three decades of experience in healthcare and technology companies. He has an extensive background in capital markets transactions, mergers and acquisitions, business development and investor relations as well as in corporate governance matters. Most recently, he served as the Chief Financial Officer of TytoCare Ltd., a privately-held company in the remote healthcare space. Prior to his role at TytoCare, Mr. Mamlok served as the Chief Financial Officer of Sol-Gel Technologies Ltd. In this role, he was responsible for an initial public offering and other capital markets transactions, as well as in-licensing and out-licensing transactions. Prior to his role at Sol-Gel, he served in other medical device companies, including Given Imaging which was acquired by Covidien plc in 2014. Mr. Mamlok holds a BA in Economics, magna cum laude, and a Master's degree in Business/Managerial Economics, both from the Tel Aviv University.
About Protalix BioTherapeutics, Inc.Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs–related diseases; and others.
Forward-Looking StatementsTo the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "expect," "anticipate," "believe," "estimate," "project," "plan," "should" and "intend" and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.
Investor ContactMike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306mmoyer@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/999479/5422505/Protalix_Biotherapeutics_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-appoints-gilad-mamlok-as-its-new-senior-vice-president-and-chief-financial-officer-302509411.html
SOURCE Protalix Biotherapeutics Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Slipstream Announces New Investment from GreyLion Partners and Denali Growth Partners
Investment further positions Slipstream for continued growth BLUE BELL, Pa., August 05, 2025--(BUSINESS WIRE)--Slipstream IT ("Slipstream"), a trusted technology partner serving the pharmaceutical and biopharmaceutical industry, today announced an investment from GreyLion Partners LP ("GreyLion"), a U.S. private equity firm focused on high-growth businesses. The investment complements Slipstream's existing equity investment from Denali Growth Partners ("DGP"), which also participated alongside GreyLion. The financing will further enable the Company to continue investing in people, systems, and processes, while expanding its offerings in new and existing markets through organic growth and potential add-on acquisitions. Terms of the transaction were not disclosed. Slipstream operates at the intersection of an increasingly complex and evolving pharmaceutical and biotech landscape, in an expanding market for outsourced IT services. This latest investment will fuel the continued growth of Slipstream's capabilities across Cloud CRM Solutions, R&D and Commercial Services, IT & End User Services, AI, and Information Management. "The dynamic pharmaceutical regulatory environment requires a need for compliant capabilities with specific expertise around the industry, and our suite of services is catered to support these unique requirements and complexities," said Brandon McKay, CEO and Founder of Slipstream. "We believe there are significant opportunities to further scale our platform. Our team is thrilled to partner with GreyLion and DGP. We look forward to leveraging their long-standing experience and expertise to help us achieve our strategic business objectives." Slipstream's mission is to empower Life Sciences organizations with pragmatic, scalable, and compliant technology solutions, enabling customers to accelerate innovation, adopt best-in-class practices, maintain digital integrity, and ultimately improve patient outcomes. Henry Heinerscheid, Partner at GreyLion, said, "We are excited for the opportunity to serve as a strategic partner to Brandon and the Slipstream management team alongside DGP for its next phase of growth." "We believe there is a significant opportunity for Slipstream to continue to scale while maintaining its focus on providing best-in-class service to life science and pharma companies," added Ryan Anderson, Partner at GreyLion. "Since partnering with Brandon and the Slipstream team in 2022, we've seen firsthand their ability to build a scalable, growing, and resilient business. They've continued to expand the platform and solutions with strategic clarity and execution. We're proud to continue to support a management team we deeply admire, and are excited about the significant growth opportunities ahead," said Jesse Lane, Founder and Managing Partner of DGP. "We are looking forward to continuing to support Slipstream and to working alongside the team at GreyLion," added Greg McDouglas, a Vice President at DGP. Legal and Financial AdvisorsKirkland & Ellis LLP served as legal counsel to the Company and advised on the Company's financing and fund matters for DGP and GreyLion. Latham & Watkins LLP represented GreyLion. Choate Hall & Stewart LLP served as legal counsel to DGP. Fox Rothschild LLP acted as counsel to management. Guggenheim Securities, LLC served as Slipstream's financial advisor. About Slipstream Slipstream is a trusted technology partner exclusively serving the Life Sciences industry. Our global team brings deep domain expertise and pragmatic, end-to-end solutions that simplify complex challenges across the entire product lifecycle. We deliver with speed, compliance, and foresight— empowering clients to accelerate research, optimize time to market, and improve patient outcomes, ensuring technology keeps pace with their life-changing mission. Learn more about Slipstream IT About GreyLion Partners LP GreyLion focuses on investing in high-growth businesses in the lower middle market across two sectors: (i) services and (ii) specialized industrial and manufacturing. The team seeks to partner with existing owners and management teams to deliver capital in tailored and flexible structures. The GreyLion partners have spent nearly two decades executing a consistent strategy of investing $25-$125 million of capital per investment, primarily within the United States. They currently manage private equity funds with aggregate commitments of approximately $2.0 billion. For more information on GreyLion, please visit About Denali Growth Partners Founded in 2021, DGP is a Boston-based growth equity firm. DGP seeks to partner with exceptional entrepreneurs who are building growing, profitable, and capital-efficient companies. As of May 1, 2025, the firm manages more than $750 million in Regulatory Assets Under Management. For more information about DGP, please visit or follow the firm on LinkedIn. View source version on Contacts Slipstream Isabella GreyLion Partners LP Jody Shechtmanjody@ Denali Growth Partners Bill Stuartinfo@
Forbes
32 minutes ago
- Forbes
How Palantir Stock Falls To $80
Palantir Technologies stock (NASDAQ: PLTR) has had a remarkable run this year, more than doubling since early January to trade at around $160 per share. The stock has been buoyed by surging interest in generative AI and a wave of new government contracts following the re-election of Donald Trump as U.S. President. Earnings momentum has also been strong: Palantir recently delivered a beat-and-raise quarter, with Q2 revenue growing 48% year-over-year to over $1 billion. The company raised its full-year revenue guidance to between $4.14 billion and $4.15 billion, up from its earlier forecast of $3.89 billion to $3.90 billion. Let's be clear. Palantir's execution has been solid. Revenue growth over the most recent quarter improved to 48%, up from 27% in the year-ago quarter, while adjusted operating margins stood at 48%, up from 37% in the year-ago quarter. But that strength is exactly why the risk is also underappreciated. When expectations are sky-high, the fall can be pretty steep. Separately, Is Figma Stock Too Risky At $120? Broader markets have rallied in recent months, but macroeconomic challenges remain, including lingering inflation, softening job numbers, and sizable import tariffs on key trading partners. Palantir's lofty valuation - roughly 255x forward earnings - makes it particularly vulnerable to a sharp pullback. Could the stock fall 50% to $80 per share or even lower? There's a real possibility. Palantir has seen steeper drawdowns in the past and those declines could easily repeat if sentiment turns. Of course, individual stocks tend to be more volatile than a diversified portfolio – so if you seek growth with less volatility than a single stock, consider the High-Quality portfolio, which has outperformed the S&P 500 and delivered returns exceeding 91% since its inception. Why Is It Relevant Now? Palantir's revenue growth risks Palantir has posted strong growth, particularly in its U.S. government segment, which saw revenue rise 53% year-over-year to $426 million over the last quarter. However, this momentum comes with risks. Government contracts tend to be lumpy and unpredictable, making future growth harder to forecast. Moreover, the new Trump administration is pursuing a strategy of de-escalating global tensions—including efforts to mediate between Ukraine and Russia and address the Israel-Palestine conflict. While these initiatives support global stability, they could reduce demand for Palantir's software, which often sees higher uptake during periods of geopolitical uncertainty. With a heavy reliance on federal contracts, Palantir remains exposed to political risk as well. Shifts in government priorities, budget cuts, or contract losses could meaningfully impact its revenue trajectory and weigh on the stock. Palantir's long-term growth depends on the commercial market, which the company caters to via its Foundry platform, which targets customers in industries including manufacturing, retail, and healthcare. While the commercial business has seen traction - with U.S. commercial sales almost doubling in the most recent quarter - there could be headwinds. The company's ticket sizes are typically large, and implementation is also complex and expensive, meaning that the product may not scale as well with small and medium-sized firms. Scaling Foundry beyond large enterprises could require a different go-to-market approach - one that Palantir isn't built for today. This could impact growth in the longer-run. How Resilient Is Palantir Stock In Downturns? During periods of economic stress, Palantir has underperformed broader markets by a wide margin. Consider 2022: Palantir stock lost over 70% of its value within a few quarters - falling from $18.53 in January to $6.00 by December. By comparison, the S&P 500 declined about 25% over the same period. To its credit, Palantir fully recovered to its pre-crisis peak by July 2023, and since then, the stock has surged to a high of $160.66 as of early August 2025. But history shows that when sentiment shifts, PLTR stock can crater. While investors have their fingers crossed for a soft landing by the U.S. economy, how bad can things get if there is another recession? Our dashboard How Low Can Stocks Go During A Market Crash captures how key stocks fared during and after the last six market crashes. Palantir's High Valuation Palantir Technologies' revenues have grown at an average annual rate of 24% over the past three years, well above the S&P 500's 5.2% growth. But even that impressive performance doesn't justify the stock's current valuation. Palantir trades at 90x FY'25 revenue and roughly 255x FY'25 earnings - multiples that leave little room for error. High-multiple growth stocks often falter during economic slowdowns, as lower earnings growth leads to sharp contractions in valuation multiples. In downturns, markets rotate toward safer value stocks, and Palantir clearly does not fit that mold. If the stock sees a correction near 2022 levels, it could fall to $80 per share or even lower. Not too happy about the volatile nature of PLTR stock? The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.
Yahoo
an hour ago
- Yahoo
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025
MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second quarter 2025 financial results on Tuesday, August 12, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at A rebroadcast of the event will be available and archived for a period of one year at the same Liquidia CorporationLiquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA™ (treprostinil) inhalation powder, a drug that has been approved for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PHILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit InformationInvestors:Jason AdairChief Business Patrick WallaceDirector, Corporate in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
